Loading
companiesCompany
Diakonos Oncology
Diakonos Oncology makes dendritic cell therapies from a patient's own cells, with trials under way in glioblastoma, pancreatic cancer and melanoma.
Overview
Diakonos Oncology develops patient-derived dendritic cell vaccines that present the patient's own tumour antigens to the immune system, and is running clinical trials in glioblastoma, pancreatic cancer and melanoma. Access is through trial enrolment.
Headquarters
United States (city not published), US
Scorecard
All companies#459of 1244 companies, score 6
- phase 1/2 +1
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 0 targets, 2 registry studies. Formula on the scorecards page.
Type
Stage
Startup
Website
Phase 2Cancer vaccine
DOC1021 is a cancer vaccine from Diakonos Oncology Corporation, in registered phase 2 trials for glioma & glioblastoma, melanoma.
Similar pages
- InstitutionImmunocine
Shares Dendritic cell vaccines and the tag fcct-directory.
- CompanyBelay Diagnostics
Shares Glioma & glioblastoma and the tag fcct-directory.
- CompanyKiyatec
Shares Glioma & glioblastoma and the tag fcct-directory.
- InstitutionCeCurio (MVZ Tübingen oncology)
Shares Glioma & glioblastoma and the tag fcct-directory.
- CompanyMedigene
Shares Dendritic cell vaccines, Pancreatic ductal adenocarcinoma.
- TermCancer vaccines and oncolytic viruses
Shares Dendritic cell vaccines, Melanoma.